Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of M834 vs Orencia in Healthy Volunteers
NCT02923583Phase 1Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Momenta Pharmaceuticals. Primary endpoints: Maximum serum concentration at Day 85, Area under the serum concentration versus time curve from zero to last quantifiable concentration at Day 85 and 1 more. Started Oct 2016; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02923583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923583.